Benzinga | Mar 2, 2021 07:11AM EST

Needham Maintains Buy on Intercept Pharmaceuticals, Lowers Price Target to $34

Needham analyst Joseph Stringer maintains Intercept Pharmaceuticals (NASDAQ:ICPT) with a Buy and lowers the price target from $80 to $34.